Published in AIDS Weekly, April 14th, 1997
The market clearance follows a recommendation of approval for the Vitrasert Implant by the Committee for Proprietary Medicinal Products (CPMP), which reviewed the product on behalf of the European Agency for the Evaluation of Medicinal Products (EMEA). The Vitrasert Implant is the first drug delivery system to provide local, sustained therapy of the eye for the treatment of cytomegalovirus (CMV) retinitis in people with AIDS.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.